See more : XXL ASA (0R3P.L) Income Statement Analysis – Financial Results
Complete financial analysis of Guard Therapeutics International AB (publ) (GUARD.ST) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Guard Therapeutics International AB (publ), a leading company in the Biotechnology industry within the Healthcare sector.
- BitNile Holdings, Inc. (NILE) Income Statement Analysis – Financial Results
- Ishihara Chemical Co., Ltd. (4462.T) Income Statement Analysis – Financial Results
- Shikoku Chemicals Corporation (4099.T) Income Statement Analysis – Financial Results
- Taylor Morrison Home Corporation (TMHC) Income Statement Analysis – Financial Results
- RLH Properties, S.A.B. de C.V. (RLHPF) Income Statement Analysis – Financial Results
Guard Therapeutics International AB (publ) (GUARD.ST)
About Guard Therapeutics International AB (publ)
Guard Therapeutics International AB (publ), a pharmaceutical company, identifies, develops, and commercializes therapies for the diagnosis and treatment of acute kidney injuries in Sweden. It offers ROSGard, a biological drug candidate that prevents kidney damage by protecting, cleaning, and repairing the exposed cells and tissues. The company was formerly known as A1M Pharma AB (publ) and changed its name to Guard Therapeutics International AB (publ) in October 2019. Guard Therapeutics International AB (publ) was incorporated in 2008 and is based in Stockholm, Sweden.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 33.00K | 715.00K | 1.25M | 28.73K |
| Cost of Revenue | 15.00K | 15.00K | 15.00K | 161.00K | 290.00K | 22.52M | 2.39M | 1.99M | 841.00K | -11.00M | -7.50M | -5.95M | -2.84M |
| Gross Profit | -15.00K | -15.00K | -15.00K | -161.00K | -290.00K | -22.52M | -2.39M | -1.99M | -841.00K | 11.04M | 8.22M | 7.20M | 2.87M |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 33,445.45% | 1,149.51% | 576.24% | 9,977.27% |
| Research & Development | 105.77M | 104.81M | 75.33M | 35.42M | 37.56M | 73.69M | 55.21M | 44.82M | 22.58M | 9.95M | 0.00 | 0.00 | 0.00 |
| General & Administrative | 5.38M | 4.97M | 3.70M | 3.08M | 3.41M | 4.75M | 3.51M | 4.33M | 2.52M | 13.26M | 9.12M | 5.85M | 0.00 |
| Selling & Marketing | 3.77M | 3.84M | 2.26M | 1.92M | 3.32M | 7.62M | 8.77M | 5.43M | 5.00M | 2.52M | 0.00 | 0.00 | 0.00 |
| SG&A | 9.15M | 8.82M | 5.96M | 5.00M | 6.72M | 12.36M | 12.28M | 9.76M | 7.52M | 13.26M | 9.12M | 5.85M | 0.00 |
| Other Expenses | 151.00K | 0.00 | 0.00 | -143.00K | 0.00 | 0.00 | 0.00 | -163.00K | -105.00K | 3.64M | 3.68M | 3.49M | 3.81M |
| Operating Expenses | 115.07M | 113.63M | 81.28M | 40.28M | 44.28M | 86.05M | 67.48M | 54.42M | 29.99M | 16.90M | 12.79M | 9.34M | 3.81M |
| Cost & Expenses | 115.07M | 113.63M | 81.28M | 40.28M | 44.28M | 86.05M | 67.48M | 54.42M | 29.99M | 5.90M | 5.29M | 3.39M | 970.72K |
| Interest Income | 2.20M | 138.00K | 20.00K | 7.00 | 872.00 | 0.00 | 0.00 | 0.00 | 3.00K | 5.00K | 114.00K | 48.00K | 7.00 |
| Interest Expense | 447.00K | 1.00K | 1.00K | 7.00K | 872.00K | 655.00K | 163.00K | 17.00K | 32.00K | 272.00K | 706.00K | 8.00K | 23.01K |
| Depreciation & Amortization | 15.00K | 15.00K | 15.00K | 161.00K | 290.00K | 22.52M | 2.39M | 1.99M | 841.00K | 101.00K | 68.00K | 11.00K | 5.64K |
| EBITDA | -114.91M | -112.82M | -82.01M | -40.12M | -43.29M | -64.19M | -65.25M | -52.43M | -29.25M | -13.52M | -4.39M | -2.08M | -936.34K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -17,548.48% | -613.99% | -166.08% | -3,258.87% |
| Operating Income | -115.07M | -114.92M | -81.90M | -40.28M | -44.28M | -86.05M | -67.48M | -54.42M | -29.99M | -5.90M | -4.57M | -2.14M | -941.99K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -17,872.73% | -639.44% | -170.80% | -3,278.54% |
| Total Other Income/Expenses | 1.75M | 2.08M | -130.00K | -7.00K | -872.00K | -656.00K | -163.00K | -17.00K | -100.00K | -267.00K | -592.00K | 118.00K | -23.00K |
| Income Before Tax | -113.32M | -112.84M | -82.03M | -40.28M | -45.16M | -86.71M | -67.64M | -54.44M | -32.45M | -6.16M | -5.16M | -2.10M | -964.99K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -18,678.79% | -722.24% | -167.60% | -3,358.59% |
| Income Tax Expense | 0.00 | -2.08M | 130.00K | 7.00K | 872.00K | 656.00K | 163.00K | -2.36M | -37.00K | 267.00K | 592.00K | -40.00K | 23.00K |
| Net Income | -113.32M | -110.76M | -82.16M | -40.29M | -46.03M | -86.71M | -67.64M | -52.08M | -32.42M | -6.16M | -5.16M | -2.10M | -964.99K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -18,678.79% | -722.24% | -167.60% | -3,358.59% |
| EPS | -11.26 | -15.72 | -18.41 | -12.15 | -22.16 | -2.69 | -5.07 | -10.65 | -8.06 | -1.88 | -2.49 | -1.01 | -0.46 |
| EPS Diluted | -11.26 | -15.72 | -18.41 | -12.15 | -22.16 | -2.69 | -5.07 | -10.65 | -8.06 | -1.88 | -2.49 | -1.01 | -0.46 |
| Weighted Avg Shares Out | 10.06M | 7.05M | 4.46M | 3.32M | 2.08M | 32.23M | 13.34M | 4.89M | 4.02M | 3.29M | 2.08M | 2.08M | 2.09M |
| Weighted Avg Shares Out (Dil) | 10.06M | 7.05M | 4.46M | 3.32M | 2.08M | 32.23M | 13.34M | 4.89M | 4.02M | 3.29M | 2.08M | 2.08M | 2.09M |
Source: https://incomestatements.info
Category: Stock Reports